ALXN Stock UPDATES Alexion Pharmaceuticals (ALXN) 168.90 08/14/2014

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Alexion Pharmaceuticals (ALXN) 168.90 $ALXN

Stock Market News for August 14, 2014 - Market News
Zacks Equity Research - Zacks Investment Research - Thu Aug 14, 9:10AM CDT
Benchmarks ended in the green as gains in biotech stocks offset discouraging retail sales numbers

Researchers to Present New Data on Asfotase Alfa in Pediatric Patients with Hypophosphatasia at the American Society for Bone and Mineral Research 2014 Annual Meeting
Business Wire - Wed Aug 13, 3:57PM CDT
Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced that new data from multiple studies of asfotase alfa in pediatric patients with hypophosphatasia (HPP) will be presented at the American Society for Bone and Mineral Research (ASBMR) 2014 Annual Meeting, which takes place September 12-15, 2014 in Houston, Texas. The meeting will feature a late-breaking abstract of survival data in pediatric patients with HPP at high risk of death who were treated with asfotase alfa, along with results from two studies in patients with perinatal, infantile and juvenile HPP who were treated with asfotase alfa for up to three years.

National Association of Professional Women Announces Donna Ames, Sr. Manager, Clinical Project Lead at Alexion Pharmaceuticals, a 2014 Professional Woman of the Year
PRWeb - Mon Aug 11, 11:03PM CDT
NAPW honors Donna Ames as a 2014 Professional Woman of the Year for coordinating clinical trials with this prestigious distinction. As the largest, most-recognized networking organization of women in the country, spanning virtually every industry and profession, the National Association of Professional Women (NAPW) is a powerfully vibrant networking community with over 600,000 members and more than 300 Local Chapters.

Alexion Pharmaceuticals Set to Possibly Pullback After Yesterday's Rally of 1.68%
Comtex SmarTrend(R) - Mon Aug 11, 4:18PM CDT
Alexion Pharmaceuticals (NASDAQ:ALXN) traded in a range yesterday that spanned from a low of $158.24 to a high of $162.18. Yesterday, the shares gained 1.7%, which took the trading range above the 3-day high of $159.60 on volume of 968,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.

Cannabis Should Be Treated as an Agricultural Commodity, Not a Biotech Investment
ACCESSWIRE - Mon Aug 11, 1:44PM CDT
Pittsburgh, PA / August 11, 2014 / While the future of cannabusiness is certainly bright, one controversial yet crucial caveat must be made. Pot stocks should be treated as an agricultural commodity investment rather than as a biotech investment. This is not to say that cannabis cannot be used as a pharmaceutical. It certainly can. Rather it should not be invested in as one would invest in a pharmaceutical. Taking a biotech strategy with pot stocks is the wrong road to take.

Earnings Look Back: Alexion Pharmaceuticals Is Down 5.0% Since Reporting Quarterly Results 2 Weeks Ago (ALXN)
Comtex SmarTrend(R) - Mon Aug 11, 12:08PM CDT
Two weeks ago on July 24th, 2014 Alexion Pharmaceuticals (NASDAQ:ALXN) reported earnings and analysts, on average, expected earnings of $1.07 on sales of $510.5 million. The company actually reported EPS of $1.12 on sales of $512.5 million, beating EPS estimates by $0.05 and beating revenue estimates by $2.0 million. Since the company's report, shares of Alexion Pharmaceuticals have fallen from $167.48 to $159.11, representing a loss of 5.0% in the past 18 days.

Biotech Equities Technical Momentum -- InterMune, Biogen Idec, Insmed, Dendreon, and Alexion Pharma
PR Newswire - Mon Aug 11, 7:40AM CDT
The trading session on Friday, August 08, 2014 ended on a higher note as the Dow Jones Industrial Average finished at 16,553.93, up 1.13% and the NASDAQ Composite closed at 4,370.90, up 0.83%. The S&P 500 finished the day 1.15% higher at 1,931.59. The gains were broad based as all the ten sectors finished on a positive note. The S&P 500 Health Care Sector Index finished the day at 699.99, up 1.14%, and the index has advanced 4.73% in the previous three months. Investor-Edge has initiated coverage on the following equities: InterMune Inc. (NASDAQ: ITMN), Biogen Idec Inc. (NASDAQ: BIIB), Insmed Inc. (NASDAQ: INSM), Dendreon Corp. (NASDAQ: DNDN), and Alexion Pharmaceuticals Inc. (NASDAQ: ALXN). Free research on these five companies can be accessed at:

Today's Stocks Driving Success For The Health Care Sector
at The Street - Fri Aug 08, 12:03PM CDT
TheStreet highlights 3 stocks pushing the health care sector higher today.

VIVUS Reports Narrower-than-Expected Loss on Qsymia Sales - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Aug 08, 10:00AM CDT
VIVUS Inc. (VVUS) reported second quarter 2014 loss (excluding one-time items) of 25 cents per share.

Orexigen Therapeutics Reports Wider Q2 Loss as Costs Mount - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Aug 08, 8:20AM CDT
Orexigen Therapeutics, Inc. (OREX) reported a net loss of 21 cents per share in the second quarter of 2014.

Here's How Facebook, Alexion Teach Lessons In Tenacity
at Investor's Business Daily - Thu Aug 07, 5:02PM CDT
Tenacity is among the more difficult yet more rewarding traits CAN SLIM investors eventually learn to cultivate. Buy-and-hold investors keep a stock as it spirals deep into a correction. They wager on faith that the stock will at some point rise to...

NPS Pharma Reports Earnings in Q2 on Strong Gattex Sales - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Aug 07, 11:40AM CDT
NPS Pharma (NPSP) reported earnings of 2 cents in the second quarter , which compared favorably with the Zacks Consensus Estimate.

Financial Results, FDA Approvals, Orphan Drug Designations, and Certificates - Research Reports on Idenix, Baxter, Alexion, Alere and Zoetis
PR Newswire - Thu Aug 07, 8:10AM CDT
Today, Analysts Review released its research reports regarding Idenix Pharmaceuticals Inc. (NASDAQ: IDIX), Baxter International Inc. (NYSE: BAX), Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN), Alere Inc. (NYSE: ALR) and Zoetis Inc. (NYSEQ: ZTS). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/5549-100free.

Watch for Alexion Pharmaceuticals to Potentially Rebound After Falling 1.52% Yesterday
Comtex SmarTrend(R) - Tue Aug 05, 5:26PM CDT
Alexion Pharmaceuticals (NASDAQ:ALXN) traded in a range yesterday that spanned from a low of $154.56 to a high of $159.75. Yesterday, the shares fell 1.5%, which took the trading range below the 3-day low of $156.21 on volume of 1.3 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.

Actavis Beats on Q2 Earnings & Revs, Provides 2015 Outlook - Analyst Blog
Arpita Dutt - Zacks Investment Research - Tue Aug 05, 1:00PM CDT
Actavis (ACT) second quarter results were boosted by the inclusion of products from the Warner Chilcott acquisition.

Alkermes Reports Loss in Q2 on Higher Costs, Revenues Up - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Aug 04, 2:40PM CDT
Alkermes (ALKS) incurred loss in the quarter due to higher expenses.

Arena Pharmaceuticals Falls on Wider-than-Expected Q2 Loss - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Aug 04, 10:10AM CDT
Arena Pharmaceuticals, Inc. (ARNA) reported a net loss (excluding one-time items) of 12 cents per share in the second quarter of 2014.

Dr. Reddy's (RDY) Q1 Earnings and Revenues Rise Y/Y - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Aug 01, 2:20PM CDT
Dr. Reddy's (RDY) reported first-quarter fiscal 2015 earnings per American Depositary Share (ADS) of 54 cents, up 52% and revenues of $586 million, up 24% from the year-ago period .

Alexion Pharmaceuticals wins European Commission's ODS for Soliris for treating Myasthenia Gravis
M2 - Fri Aug 01, 7:07AM CDT
Biopharmaceutical company Alexion Pharmaceuticals (NasdaqGS:ALXN) revealed on Friday the receipt of the European Commission's orphan drug designation (ODD) for Soliris (eculizumab) for the treatment of patients with Myasthenia Gravis (MG), a rare, debilitating neurologic disorder caused by uncontrolled complement activation.

European Commission Grants Orphan Drug Designation to Soliris(R) (eculizumab) for the Treatment of Patients with Myasthenia Gravis (MG)
Business Wire - Fri Aug 01, 5:30AM CDT
Alexion Pharmaceuticals (NASDAQ:ALXN) today announced that the European Commission has granted orphan drug designation (ODD) to Soliris(R) (eculizumab) for the treatment of patients with Myasthenia Gravis (MG), a rare, debilitating neurologic disorder caused by uncontrolled complement activation. In patients with MG, uncontrolled complement activation due to antibodies directed at the neuromuscular junction can ultimately lead to profound and debilitating weakness of various muscle groups throughout the body.




Scroll down for more posts ▼

Top 10 Most Recent News Articles

California Stone Ban Puts a Hidden Worker Toll in View

Updated Category News Views 5

Countertops are supposed to finish a kitchen, not quietly wreck the lungs of the people cutting them. Yet California's move toward prohibiting the fabrication and installation of artificial stone containing more than 1% crystalline silica puts an ugly, long-running occupational-health problem in plain sight. This is not a story that calls for chest-thumping market talk....

Continue Reading
Pennsylvania Housing Finds Its October Holding Pattern

Updated Category News Views 79

Pennsylvania's October housing numbers have the uneasy stillness of a pond before somebody throws a rock. The statewide median sales price sat at $315,000, exactly where it was in September, while sales barely cleared 10,400 and available listings kept inching higher. Nothing in that mix screams boom or bust. Frankly, that is the point: a market can look calm on the...

Continue Reading
D-Wave Investors Face December 15 Lead Plaintiff Clock

Updated Category News Views 83

Quantum dreams met a very earthly spreadsheet problem at D-Wave this summer. The proposed securities class action against D-Wave Quantum Inc. puts a hard date on the issue for investors who bought shares between February 26 and August 25, 2026: December 15, 2026 is the deadline to seek lead-plaintiff status. That does not mean every holder needs to march into court. It...

Continue Reading
Dario's Personify Panel Puts Distribution Model in Focus

Updated Category News Views 229

A Partner Megaphone Is Not a Revenue Line Monday's virtual panel gives DarioHealth a useful stage, but investors should not confuse a conference microphone with a signed sales order. Erez Raphael is set to lead a November 23 discussion with Personify Health President Ed Liebowitz at the U.S. Bancorp | BTIG Tech-Enabled Healthcare Forum, running from noon to 12:50 p.m....

Continue Reading
HVAC’s $383.6 Billion Shift Is About More Than Units

Updated Category News Views 163

Server racks are turning cooling gear into a front-row industrial story, and that deserves more attention than the usual sleepy talk about replacement air conditioners. Frost & Sullivan projects the global HVAC equipment market will reach $383.6 billion by 2031, growing at a 7.0% compound annual rate from 2025. That is a sizable market, sure, but the more interesting...

Continue Reading
Wenge AI Removes a Small Friction Point for ScienceOra

Updated Category News Views 84

Scientific software rarely loses users because the underlying model is too clever; it loses them because getting through the front door is a nuisance. Wenge AI has addressed that unglamorous problem by adding Google and Apple sign-in options to the international version of ScienceOra, its AI-powered research and decision-support platform. This is not the sort of...

Continue Reading
Pepsi Faces Georgia Labor Pressure Ahead of Strike

Updated Category News Views 5

A Pre-Dawn Labor Test Is Brewing in Georgia At 2:30 in the morning, nobody gathers outside a distribution center for the scenery. More than 100 Pepsi-Cola drivers from Atlanta and Lithonia are slated to meet Tuesday, November 24, at the Pepsi Distribution Center in Lithonia, Georgia, with Teamsters General President Sean M. O'Brien joining them. That hour matters. It puts...

Continue Reading
Cloud Security’s $26.8 Billion Test Is All About Execution

Updated Category News Views 59

A cloud dashboard that spits out ten thousand alerts is not protection; it is an expensive way to make a security team miserable. That frustration sits right in the middle of Frost & Sullivan’s projection that global cloud security revenue will climb from $8.4 billion in 2025 to $26.8 billion by 2031, a 21.4% compound annual growth rate. The number is hefty, no...

Continue Reading
AI Governance Is Becoming Enterprise Infrastructure

Updated Category News Views 43

Governance Has Finally Reached the Engine Room Enterprise AI is no longer a shiny pilot parked in some innovation lab; it is creeping into business-critical work, and that changes the argument entirely. Frost & Sullivan’s latest analysis makes a sensible point that too many executives still resist: AI governance is becoming a strategic operating capability, not merely a...

Continue Reading
Healthcare's Prevention Puzzle Needs Better Incentives

Updated Category News Views 60

When Savings Belong to the Next Plan A patient changing insurance plans can turn prevention into nobody’s asset. That is the uncomfortable little engine inside Russell Greenfield’s recent argument: an insurer may pay today for a program that helps prevent chronic illness, only to watch the eventual savings land with another plan after the member moves on. The person...

Continue Reading

Top 5 Most Recently Viewed Articles

Indovinya Unveils Challenge for Innovative Fragrance Solutions

Updated Category News Views 148

Indovinya Launches Open Innovation Challenge Researchers and startups with a focus on developing sustainable solutions for fragrance solubilization are invited to apply for an exciting new challenge initiated by Indovinya, the specialty chemicals and surfactants division of Indorama Ventures. The aim is to enhance fragrance solubilization without the use of ethoxylates,...

Continue Reading
Capricor Therapeutics to Highlight Innovations at Investor Events

Updated Category News Views 156

Capricor Therapeutics to Highlight Innovations at Investor Events Capricor Therapeutics (NASDAQ: CAPR), a leading biotechnology company based in San Diego, is committed to developing transformative cell and exosome-based therapies aimed at addressing rare diseases. Recently, the company announced a series of presentations scheduled at prominent investor conferences, where...

Continue Reading
Trump Media Takes Bold Step Into Financial Sector with New ETFs

Updated Category News Views 179

Trump Media's Financial Leap Trump Media & Technology Group Corp. (NASDAQ: DJT) is embarking on an exciting journey into the financial landscape. The company's fintech and streaming divisions are rolling out an innovative suite of five new exchange-traded funds (ETFs). These funds are crafted around the compelling themes of 'America First', aiming to appeal to socially...

Continue Reading
Vascular Access Device Market Set to Hit $8.68 Billion Milestone

Updated Category News Views 133

Overview of the Vascular Access Device Market The vascular access device market is on a promising trajectory, projected to escalate from around USD 6.27 billion to USD 8.68 billion by 2031, reflecting a compound annual growth rate (CAGR) of 6.7%. This significant growth is positioned to enhance patient care in various healthcare settings, emphasizing the vital role of...

Continue Reading
Oscar Health: Navigating the Storm in Health Insurance Market

Updated Category News Views 269

Oscar Health: Understanding the Current Landscape The US health insurance sector is facing unprecedented challenges this year. With a significant number of individuals at risk of losing health insurance coverage due to substantial budget cuts, many are seeking medical care while they still can. This surge in demand has resulted in soaring utilization rates, pushing...

Continue Reading